流感特效药速福达再度紧俏 罗氏：已启动应对预案 今年整体供应量是去年的3倍以上

Core Viewpoint - The demand for the new generation antiviral drug, Sufuda, is rising as flu activity increases across multiple regions in China, prompting Roche to implement a comprehensive response plan to ensure supply stability [1]. Group 1: Supply Chain and Production - Roche has initiated local production of Sufuda in Shanghai to fundamentally shorten supply chain times and enhance supply flexibility, as the drug was previously imported [1]. - The company has mobilized global supply chain resources to increase production and expedite shipments to the Chinese market during the flu season [1]. - Sufuda's overall supply this year is more than three times that of the previous year, with Roche conducting flexible and dynamic supply adjustments based on actual demand across the country [1]. Group 2: Emergency Response and Distribution - Roche has prepared emergency plans with distributors to respond quickly to any sudden spikes in flu cases, ensuring timely delivery of medications to healthcare institutions [1]. - Both Sufuda and the original antiviral Oseltamivir (brand name: Tamiflu) have achieved widespread hospital access across the nation [1].